56
Participants
Start Date
February 15, 2021
Primary Completion Date
February 22, 2022
Study Completion Date
February 22, 2022
ACD856
Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
Placebo
Placebo oral solution
ACD856 (fed cohort)
Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
Uppsala University Hospital, Uppsala
Lead Sponsor
AlzeCure Pharma
INDUSTRY